
Dihexa is a small-molecule angiotensin IV analogue studied for activity at the hepatocyte growth factor / c-Met signalling system, a pathway associated in the literature with synaptogenesis. Supplied as pre-dosed capsules.
| Form | Oral capsules — pre-dosed, no reconstitution |
| Purity | ≥99% (verified) |
| Storage | Cool and dry, sealed; protect from light |
| Batch | COA available on request |
Dihexa is a small-molecule angiotensin IV analogue studied for activity at the hepatocyte growth factor / c-Met signalling system, a pathway associated in the literature with synaptogenesis. Supplied as pre-dosed capsules.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small-molecule analogue derived from angiotensin IV. It was developed specifically to address the problem that limits most peptide neuroscience research: angiotensin IV itself is degraded rapidly and crosses the blood-brain barrier poorly.
The structural modifications — an N-terminal hexanoic acid group and a C-terminal amide — were made to improve metabolic stability and lipophilicity. That design goal is why it appears in the literature as an orally-oriented compound rather than an injectable one.
Supplied as pre-dosed capsules for laboratory research use only. Not for human consumption.
The mechanism most consistently reported is potentiation of hepatocyte growth factor at its receptor, c-Met. Rather than acting as a direct agonist, published work describes Dihexa augmenting HGF's own activity at the receptor — which is a different pharmacological proposition from a conventional agonist.
The HGF/c-Met system is associated in neuroscience literature with dendritic spine formation and synaptic connectivity. Studies have examined synapse formation in hippocampal culture, which is the endpoint most often cited in discussions of the compound.
A substantial part of the published interest concerns pharmacokinetics rather than pharmacodynamics — specifically whether the structural modifications achieve meaningful central nervous system exposure where the parent peptide does not.
Angiotensin IV has its own literature in learning and memory models. Dihexa is studied partly as a tool for asking whether that activity survives the modifications made for stability.
The literature on Dihexa is preclinical and comparatively small — rodent models and cell culture. It has not entered human clinical trials and is not an approved drug in any jurisdiction.
| State | Temperature | Practical shelf life |
|---|---|---|
| Sealed bottle, room temperature | 15–25 °C | To printed expiry |
| Sealed bottle, refrigerated | 2–8 °C | To printed expiry |
| Opened bottle, tightly closed | 15–25 °C | Months, if kept dry |
| Exposed to humidity | any | Degrades — discard |
Oral dosage forms are considerably more forgiving than lyophilized peptides. Capsules and tablets are stable at room temperature and require no cold chain, in transit or in storage.
Moisture is the real enemy rather than temperature. Keep the bottle tightly closed, leave the desiccant sachet in place, and avoid storing in a bathroom or anywhere humidity swings. Protect from direct light.
Every lot is tested by an independent laboratory before release. HPLC establishes purity as a percentage of total content, separating the target compound from synthesis by-products; mass spectrometry confirms molecular identity.
For an encapsulated product there is a second question a vial does not raise: content uniformity. A capsule can be the right compound at the right purity and still be filled inconsistently, so Dihexa is checked for fill weight consistency across the batch as well as for identity and purity.
The certificate of analysis references the lot number printed on your bottle label. Request it at [email protected].
Join the list for restock notifications on high-demand compounds, new lot announcements with COA links, and subscriber-only pricing.